STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,741,147 | -13.7% | 188,640 | +20.0% | 0.37% | +33.6% |
| Q3 2022 | $2,018,000 | -74.3% | 157,200 | -32.6% | 0.28% | -47.3% |
| Q2 2021 | $7,847,000 | +34.0% | 233,135 | +54.7% | 0.53% | +18.3% |
| Q1 2021 | $5,854,000 | +838.1% | 150,729 | +453.1% | 0.45% | +475.6% |
| Q1 2020 | $624,000 | -91.4% | 27,254 | -89.4% | 0.08% | -87.0% |
| Q4 2019 | $7,261,000 | -1.7% | 256,380 | -26.0% | 0.60% | -47.6% |
| Q3 2019 | $7,384,000 | -24.0% | 346,380 | -1.3% | 1.14% | -14.1% |
| Q2 2019 | $9,718,000 | – | 350,944 | – | 1.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $475,340,000 | 79.82% |
| RTW INVESTMENTS, LP | 3,544,248 | $100,373,000 | 3.79% |
| Cormorant Asset Management, LP | 1,788,643 | $50,654,000 | 2.02% |
| RA Capital Management | 1,119,963 | $31,717,000 | 0.96% |
| Redmile Group, LLC | 1,020,778 | $28,908,000 | 0.69% |
| SPHERA FUNDS MANAGEMENT LTD. | 256,380 | $7,261,000 | 0.60% |
| GILDER GAGNON HOWE & CO LLC | 1,826,890 | $51,738,000 | 0.54% |
| Perceptive Advisors | 671,978 | $19,030,000 | 0.38% |
| Casdin Capital, LLC | 130,000 | $3,682,000 | 0.34% |
| Granite Point Capital Management, L.P. | 13,200 | $374,000 | 0.06% |